La cadena de opciones muestra datos clave de las opciones de acciones de Hubbell a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Hubbell..

Hubbell (NYSE:HUBB) Bolsa, Cadena de Opciones

Hubbell

Founded in 1888 by Harvey Hubbell, the eponymous company was the conduit through which the pull-chain lamp socket was originally sold. Hubbell has since grown into an electricity transmission and distribution behemoth, housing more than 75 brands that sell components found on power lines, electrical substations, and within commercial and industrial buildings. The company's primary operations are within the United States, where around 90% of revenue is derived.

Hubbell Inc

Hubb Ventures Inc

News

Guidance

KFRC

Kforce Sees Q2 GAAP EPS $0.57-$0.65 vs $0.66 Est; Sees Sales $332.000M-$340.000M vs $339.85M Est

<p>SBA Communications (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBAC#NASDAQ">SBAC</a>) lowers FY2025 sales outlook from $2.69 billion-$2.73 billion to $2.04 billion-$2.07 billion vs $2.72 billion estimate.</p>


SBAC

SBA Communications Lowers FY2025 Sales Guidance from $2.69B-$2.73B to $2.04B-$2.07B vs $2.72B Est

<p>Cadence Design Sys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNS#NASDAQ">CDNS</a>) reported quarterly earnings of $1.57 per share which beat the analyst consensus estimate of $1.49 by 5.37 percent. This is a 34.19 percent increase over earnings of $1.17 per share from the same period last year.  The company reported quarterly sales of $1.24 billion which met the analyst consensus estimate.  This is a 23.09 percent increase over sales of $1.01 billion the same period last year.</p>


Earnings

Earnings Beats

CDNS

Cadence Design Sys Q1 Adj. EPS $1.57 Beats $1.49 Estimate, Sales $1.24B Inline

<p>Firstsun Capital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSUN#NASDAQ">FSUN</a>) reported quarterly earnings of $0.83 per share which beat the analyst consensus estimate of $0.80 by 3.75 percent. This is a 56.6 percent increase over earnings of $0.53 per share from the same period last year.  The company reported quarterly sales of $96.21 million which missed the analyst consensus estimate of $99.46 million by 3.27 percent.  This is a 2.77 percent increase over sales of $93.61 million the same period last year.</p>


Earnings Misses

FSUN

Firstsun Capital Q1 Adj. EPS $0.83 Beats $0.80 Estimate, Sales $96.21M Miss $99.46M Estimate

<p><i>Nurix's DEL-AI platform uses a first-in-class DEL Foundation Model trained on the&nbsp;Company's proprietary DNA encoded library data</i></p>
<p><i>Nurix's DEL Foundation Model can accurately predict novel binders to therapeutically relevant targets, including many targets considered undruggable, with the potential to accelerate the discovery of novel drugs</i></p>
<p>SAN FRANCISCO, April 28, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRIX#NASDAQ">NRIX</a>), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today presented data that demonstrate the potential of its DEL Foundation Model to enable the rapid <i>in silico</i> identification of novel binders for a broad range of therapeutically relevant proteins, addressing a key barrier in the discovery and development of small molecule drugs. These results were presented at the American Association of Cancer Research (AACR) Annual Meeting in Chicago, IL, which is being held from April 25-30, 2025.</p>


NRIX

Nurix Therapeutics Presents Data at AACR 2025 Highlighting Transformative Potential of Proprietary DEL-AI Platform Leveraging Machine Learning To Speed Discovery Of Novel Drugs

<p>Jakks Pacific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAKK#NASDAQ">JAKK</a>) is gearing up to announce its quarterly earnings on Tuesday, 2025-04-29. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Jakks Pacific will report an <strong>earnings per share</strong> (EPS) of $-1.29.</p>
<p>The announcement from Jakks Pacific is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Overview of Past Earnings</h3>
<p>During the last quarter, the company reported an EPS beat by $0.06, leading to a 13.83% drop in the share price on the subsequent day.</p>
<p>Here's a look at Jakks Pacific's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.73</td>
<td>4.03</td>
<td>0.86</td>
<td>-0.85</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.67</td>
<td>4.79</td>
<td>0.65</td>
<td>-1.09</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-14.000000000000002%</td>
<td>15.0%</td>
<td>16.0%</td>
<td>-16.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745870572_0.png" alt="eps graph" /></p>
<h3>Tracking Jakks Pacific's Stock Performance</h3>
<p>Shares of Jakks Pacific were trading at $19.96 as of April 25. Over the last 52-week period, shares are up 3.65%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analysts' Perspectives on Jakks Pacific</h3>
<p>For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Jakks Pacific.</p>
<p>Analysts have provided Jakks Pacific with 4 ratings, resulting in a consensus rating of Buy. The average one-year price target stands at $40.0, suggesting a potential 100.4% upside.</p>
<h3>Comparing Ratings Among Industry Peers</h3>
<p>The following analysis focuses on the analyst ratings and average 1-year price targets of Funko, MasterCraft Boat Hldgs and Clarus, three prominent industry players, providing insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Buy trajectory for Funko, with an average 1-year price target of $13.0, suggesting a potential 34.87% downside.</li>
<li>Analysts currently favor an Neutral trajectory for MasterCraft Boat Hldgs, with an average 1-year price target of $19.33, suggesting a potential 3.16% downside.</li>
<li>Analysts currently favor an Buy trajectory for Clarus, with an average 1-year price target of $5.67, suggesting a potential 71.59% downside.</li>
</ul>
<h3>Peers Comparative Analysis Summary</h3>
<p>The peer analysis summary offers a detailed examination of key metrics for Funko, MasterCraft Boat Hldgs and Clarus, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jakks Pacific</td>
<td>Buy</td>
<td>2.63%</td>
<td>$35.55M</td>
<td>-3.72%</td>
</tr>
<tr>
<td>Funko</td>
<td>Buy</td>
<td>0.86%</td>
<td>$124.40M</td>
<td>-0.64%</td>
</tr>
<tr>
<td>MasterCraft Boat Hldgs</td>
<td>Neutral</td>
<td>-29.39%</td>
<td>$10.89M</td>
<td>1.55%</td>
</tr>
<tr>
<td>Clarus</td>
<td>Buy</td>
<td>-6.66%</td>
<td>$23.86M</td>
<td>-24.20%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Jakks Pacific ranks at the bottom for Revenue Growth among its peers. It is in the middle for Gross Profit. For Return on Equity, it is at the bottom.</p>
<h3>Get to Know Jakks Pacific Better</h3>
<p>Jakks Pacific Inc is a multi-product line, multi-brand toy company that designs, produces, markets, sells and distributes toys and related kid-targeted consumer products, inclusive of kids indoor and outdoor furniture, costumes and various product lines in the sporting goods and home furnishings space. Its products offering include Traditional toys and electronics such as Action figures, Toy vehicles, Dolls and accessories, Ride-on toys, Toys for pets, and others. The company's products have been divided into two segments: (i) Toys/Consumer Products and (ii) Costumes.</p>
<h3>Jakks Pacific: Delving into Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Jakks Pacific displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately <strong>2.63%</strong>. This indicates a notable increase in the company's top-line earnings. When compared to others in the Consumer Discretionary sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Jakks Pacific's net margin excels beyond industry benchmarks, reaching <strong>-6.97%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Jakks Pacific's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>-3.72%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Jakks Pacific's ROA excels beyond industry benchmarks, reaching <strong>-1.88%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.24</strong>.</p>
<p><a href="https://www.benzinga.com/quote/JAKK/earnings"><strong>To track all earnings releases for Jakks Pacific visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


JAKK

A Look Ahead: Jakks Pacific's Earnings Forecast

Kforce Q1 EPS $0.45 Misses $0.47 Estimate, Sales $330.00M Miss $333.82M Estimate

Management

MATX

Matson Announces That Rusty Rolfe, Executive Vice President Of Matson And President of Matson Logistics, Will Retire on July 1, 2025; Jerome Holland Will Succeed Rolfe

<p><strong>Kiniksa Pharmaceuticals</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KNSA#NASDAQ">KNSA</a>) is set to give its latest quarterly earnings report on Tuesday, 2025-04-29. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Kiniksa Pharmaceuticals will report an <strong>earnings per share</strong> (EPS) of $0.28. </p>
<p>Investors in Kiniksa Pharmaceuticals are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Earnings History Snapshot</h3>
<p>The company's EPS missed by $0.25 in the last quarter, leading to a 0.15% drop in the share price on the following day.</p>
<p>Here's a look at Kiniksa Pharmaceuticals's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.13</td>
<td>0.03</td>
<td>-0.07</td>
<td>-0.16</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.12</td>
<td>-0.18</td>
<td>-0.06</td>
<td>-0.25</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-0.0%</td>
<td>-1.0%</td>
<td>-4.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745870561_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of Kiniksa Pharmaceuticals were trading at $21.365 as of April 25. Over the last 52-week period, shares are up 14.74%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analysts' Take on Kiniksa Pharmaceuticals</h3>
<p>For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Kiniksa Pharmaceuticals.</p>
<p>Kiniksa Pharmaceuticals has received a total of 2 ratings from analysts, with the consensus rating as Buy. With an average one-year price target of $37.0, the consensus suggests a potential 73.18% upside.</p>
<h3>Analyzing Analyst Ratings Among Peers</h3>
<p>In this analysis, we delve into the analyst ratings and average 1-year price targets of  and Travere Therapeutics, three key industry players, offering insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Buy trajectory for Travere Therapeutics, with an average 1-year price target of $40.75, suggesting a potential 90.73% upside.</li>
</ul>
<h3>Peers Comparative Analysis Summary</h3>
<p>The peer analysis summary offers a detailed examination of key metrics for  and Travere Therapeutics, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kiniksa Pharmaceuticals</td>
<td>Buy</td>
<td>46.93%</td>
<td>$184.76M</td>
<td>-2.03%</td>
</tr>
<tr>
<td>Travere Therapeutics</td>
<td>Buy</td>
<td>65.98%</td>
<td>$72.23M</td>
<td>-421.09%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Kiniksa Pharmaceuticals ranks higher than its peers in Revenue Growth and Gross Profit, indicating stronger financial performance in these areas. However, it lags behind in Return on Equity compared to its peers. Overall, Kiniksa Pharmaceuticals is positioned in the middle among its peers based on the provided metrics.</p>
<h3>Discovering Kiniksa Pharmaceuticals: A Closer Look</h3>
<p>Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.</p>
<h3>Kiniksa Pharmaceuticals's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization Analysis:</strong> Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.</p>
<p><strong>Revenue Growth:</strong> Kiniksa Pharmaceuticals's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of <strong>46.93%</strong>. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>-7.25%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Kiniksa Pharmaceuticals's ROE excels beyond industry benchmarks, reaching <strong>-2.03%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Kiniksa Pharmaceuticals's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>-1.57%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.02</strong>.</p>
<p><a href="https://www.benzinga.com/quote/KNSA/earnings"><strong>To track all earnings releases for Kiniksa Pharmaceuticals visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


KNSA

Examining the Future: Kiniksa Pharmaceuticals's Earnings Outlook

<p>Woodward (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WWD#NASDAQ">WWD</a>) raises FY2025 Adj EPS guidance from $5.85-$6.25 to $5.95-$6.25 vs $6.18 analyst estimate. Raises FY2025 sales outlook from $3.30 billion-$3.50 billion to $3.38 billion-$3.50 billion vs $3.40 billion estimate.</p>


Woodward Raises FY2025 Adj EPS Guidance from $5.85-$6.25 to $5.95-$6.25 vs $6.18 Est; Raises FY2025 Sales Guidance from $3.30B-$3.50B to $3.38B-$3.50B vs $3.40B Est

<p>World Acceptance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WRLD#NASDAQ">WRLD</a>) is gearing up to announce its quarterly earnings on Tuesday, 2025-04-29. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that World Acceptance will report an <strong>earnings per share</strong> (EPS) of $5.84.</p>
<p>The market awaits World Acceptance's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Performance in Previous Earnings</h3>
<p>During the last quarter, the company reported an EPS beat by $0.49, leading to a 4.12% drop in the share price on the subsequent day.</p>
<p>Here's a look at World Acceptance's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2025</strong></th>
<th><strong>Q2 2025</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.96</td>
<td>1.99</td>
<td>1.69</td>
<td>4.34</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>2.45</td>
<td>3.99</td>
<td>1.79</td>
<td>6.09</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-4.0%</td>
<td>-1.0%</td>
<td>-18.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745870539_0.png" alt="eps graph" /></p>
<h3>Market Performance of World Acceptance's Stock</h3>
<p>Shares of World Acceptance were trading at $134.15 as of April 25. Over the last 52-week period, shares are down 0.78%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/WRLD/earnings"><strong>To track all earnings releases for World Acceptance visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


WRLD

Uncovering Potential: World Acceptance's Earnings Preview

<p><strong>Mark Cuban</strong> isn't sitting on the sidelines when it comes to <a href="https://www.benzinga.com/news/25/04/44658207/mark-cuban-says-cost-plus-drugs-faces-price-hike-threat-tariffs-would-force-us-to-pass-costs-directly-to-consumers">healthcare reform</a> — and he's got six plays ready to run. After President <strong>Donald Trump</strong> <a href="https://www.whitehouse.gov/fact-sheets/2025/04/fact-sheet-president-donald-j-trump-announces-actions-to-lower-prescription-drug-prices/">announced a new executive order</a> targeting healthcare costs, Cuban jumped in with rare praise, calling it a potential <a href="https://www.benzinga.com/markets/25/04/44866755/mark-cuban-says-this-trump-healthcare-order-could-save-hundreds-of-billions">game-changer for drug pricing</a>.</p>
<p>"Gotta be honest," <a href="https://x.com/mcuban/status/1912628036668739778">Cuban posted on X</a>. "The @realDonaldTrump EO on healthcare and in particular, drug pricing could save hundreds of billions."</p>
<p><strong>Don't Miss:</strong></p>
<ul>
<li><strong>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2"><strong>Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</strong></a></strong></li>
<li><strong><a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a></strong><strong> Here&#8217;s what Americans think you need to be considered wealthy.</strong></li>
</ul>
<p>And he wasn't just tossing compliments. He laid out exactly how it could happen — starting with a hard <a href="https://www.benzinga.com/personal-finance/25/04/44839817/billionaire-mark-cuban-says-pharma-is-the-easiest-business-ive-ever-disrupted-in-a-500-billion-industry-1-is-a-whole-lot-of-money">reset on how prescription drugs are priced</a>, sold, and managed.</p>
<p>Here's the gist of Cuban's six-part game plan:</p>
<h2 class="wp-block-heading">Take Formularies Away From PBMs</h2>
<p>First, Cuban said it's time to "divorce formularies from PBMs." In plain English, that means pharmacy benefit managers — the middlemen between drugmakers and insurance plans — shouldn't be the ones deciding what drugs get covered. Instead, independent groups with no financial ties should be in charge.</p>
<p>"They should be about wellness, not pay-for-play like a grocery store endcap," Cuban said. No more rebates, no more shady deals — just pricing that actually reflects patient care.</p>
<h2 class="wp-block-heading">Give Claims Data to the People Who Need It</h2>
<p>Right now, PBMs guard insurance claims data like it's the crown jewels. Cuban called that "insane." He wants PBMs to be forced to hand over all claims data to employers, states, and drugmakers — the ones who can actually use it to improve treatments.</p>
<p><strong>Trending: It&#8217;s no wonder Jeff Bezos holds over $250 million in art — <a href="https://www.benzinga.com/money/masterworks"><strong>this alternative asset has outpaced the S&amp;P 500 since 1995, delivering an average annual return of 11.4%. Here&#8217;s how everyday investors are getting started.</strong></a></strong></p>
<p>Manufacturers already pay 5% to 10% of a drug's retail price just to buy data they should've gotten for free, Cuban pointed out. Ending that would mean savings baked right into lower prices.</p>
<h2 class="wp-block-heading">Kill the ‘Specialty Tier' and Pharmacy Restrictions</h2>
<p>Cuban didn't pull punches here: "There is nothing special about specialty drugs." He said drug companies slap the "specialty" label on medications just to jack up prices. His fix? Get rid of the specialty tier system and let patients buy from any pharmacy — not just the one PBMs pick to pad their profits.</p>
<h2 class="wp-block-heading">Protect Independent Pharmacies</h2>
<p>Pharmacies that aren't tied to giant corporations are getting crushed, and Cuban says the system is rigged against them. He wants brand-name drug reimbursements fully restored and the "Generic Cost Ratio" junked — a sneaky loophole that lets distributors hike prices on generic meds.</p>
<h2 class="wp-block-heading">End Confidentiality Clauses</h2>
<p>Believe it or not, Cuban says companies can't even talk directly to drugmakers about better deals or wellness programs because of confidentiality clauses. "It's insane that your company can't talk to a GLP1 manufacturer (as an example) to help you put together a wellness plan and get you a better price," he said. He wants that nonsense scrapped.</p>
<p><strong><em>See Also: Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel"><strong><em>invest pre-IPO from $0.60 per share now</em></strong></a></em></strong><strong><em>.</em></strong></p>
<h2 class="wp-block-heading">Stop Shady Biosimilar Substitution Calls</h2>
<p>Last but not least, Cuban blasted PBMs for playing dirty with biosimilar drugs — cheaper alternatives to expensive biologics. They're supposed to offer lower-cost options, but Cuban says PBMs push their own higher-margin versions instead. They even call doctors to swap prescriptions behind the scenes.</p>
<p>"And because employers and manufacturers don't get their data," Cuban said, "they never know."</p>
<p>At the end of his post, Cuban added: "Put me in coach! I'm here to help."</p>
<p>Mark Cuban isn't just tossing out ideas — he's practically pacing the sidelines, ready to check in. Whether anyone hands him a clipboard remains to be seen, but there's still time on the clock and Cuban's ready to run a full-court press on a system that's been coasting for too long.</p>
<p>Cuban's <strong>Cost Plus Drugs</strong> model — which cuts out middlemen and sells medications directly to consumers — could gain serious credibility if broader reforms start to reshape the industry. While his company is already pushing for more transparency and lower drug prices, <a href="https://www.benzinga.com/news/25/04/44885628/mark-cuban-says-health-insurance-shouldnt-exist-you-dont-have-to-grab-every-nickel-when-its-the-health-of-the-entire-country-at-stake">Cuban's bigger healthcare ambitions are clear</a>: he's not just trying to build a better pharmacy, he's pushing for a system that actually works for patients — with or without a government playbook.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong>Can you guess how many Americans successfully retire with $1,000,000 saved?<a href="https://www.benzinga.com/money/1milsaved"><strong> The percentage may shock you</strong></a>.</strong></li>
<li><strong>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2"><strong>You can invest today for just $0.26/share with a $1000 minimum.</strong></a></strong></li>
</ul>
<p><em><strong>Image: Shutterstock</strong></em></p>


Personal Finance

Mark Cuban Lists 6 Big Fixes That Could Save 'Hundreds of Billions' Under Trump's New Healthcare Order — 'Put Me In, Coach!'

<p><strong>LGI Homes</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGIH#NASDAQ">LGIH</a>) is set to give its latest quarterly earnings report on Tuesday, 2025-04-29. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that LGI Homes will report an <strong>earnings per share</strong> (EPS) of $0.63. </p>
<p>Investors in LGI Homes are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Earnings History Snapshot</h3>
<p>In the previous earnings release, the company missed EPS by $0.03, leading to a 2.68% drop in the share price the following trading session.</p>
<p>Here's a look at LGI Homes's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>2.18</td>
<td>2.54</td>
<td>2.17</td>
<td>1.06</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>2.15</td>
<td>2.95</td>
<td>2.48</td>
<td>0.72</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-3.0%</td>
<td>-1.0%</td>
<td>-4.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745870531_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of LGI Homes were trading at $59.45 as of April 25. Over the last 52-week period, shares are down 33.89%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/LGIH/earnings"><strong>To track all earnings releases for LGI Homes visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


LGIH

What to Expect from LGI Homes's Earnings

<p>Benchmark Electronics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHE#NYSE">BHE</a>) is preparing to release its quarterly earnings on Tuesday, 2025-04-29. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect Benchmark Electronics to report an <strong>earnings per share</strong> (EPS) of $0.50.</p>
<p>The announcement from Benchmark Electronics is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Earnings History Snapshot</h3>
<p>During the last quarter, the company reported an EPS beat by $0.05, leading to a 2.59% drop in the share price on the subsequent day.</p>
<p>Here's a look at Benchmark Electronics's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.56</td>
<td>0.54</td>
<td>0.51</td>
<td>0.46</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.61</td>
<td>0.57</td>
<td>0.57</td>
<td>0.55</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-3.0%</td>
<td>-5.0%</td>
<td>18.0%</td>
<td>18.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745870523_0.png" alt="eps graph" /></p>
<h3>Performance of Benchmark Electronics Shares</h3>
<p>Shares of Benchmark Electronics were trading at $38.23 as of April 25. Over the last 52-week period, shares are up 25.98%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. </p>
<h3>Insights Shared by Analysts on Benchmark Electronics</h3>
<p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Benchmark Electronics.</p>
<p>The consensus rating for Benchmark Electronics is Buy, derived from 1 analyst ratings. An average one-year price target of $50.0 implies a potential 30.79% upside.</p>
<h3>Comparing Ratings with Competitors</h3>
<p>In this analysis, we delve into the analyst ratings and average 1-year price targets of TTM Technologies, Kimball Electronics and IPG Photonics, three key industry players, offering insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Buy trajectory for TTM Technologies, with an average 1-year price target of $33.0, suggesting a potential 13.68% downside.</li>
<li>Analysts currently favor an Buy trajectory for Kimball Electronics, with an average 1-year price target of $21.0, suggesting a potential 45.07% downside.</li>
<li>Analysts currently favor an Buy trajectory for IPG Photonics, with an average 1-year price target of $73.67, suggesting a potential 92.7% upside.</li>
</ul>
<h3>Snapshot: Peer Analysis</h3>
<p>In the peer analysis summary, key metrics for TTM Technologies, Kimball Electronics and IPG Photonics are highlighted, providing an understanding of their respective standings within the industry and offering insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Benchmark Electronics</td>
<td>Buy</td>
<td>-4.99%</td>
<td>$67.92M</td>
<td>1.66%</td>
</tr>
<tr>
<td>TTM Technologies</td>
<td>Buy</td>
<td>14.40%</td>
<td>$126.54M</td>
<td>0.33%</td>
</tr>
<tr>
<td>Kimball Electronics</td>
<td>Buy</td>
<td>-15.16%</td>
<td>$23.43M</td>
<td>0.63%</td>
</tr>
<tr>
<td>IPG Photonics</td>
<td>Buy</td>
<td>-21.60%</td>
<td>$90.34M</td>
<td>0.38%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Benchmark Electronics is positioned at the top for Gross Profit and Return on Equity among its peers. It ranks in the middle for Revenue Growth.</p>
<h3>Discovering Benchmark Electronics: A Closer Look</h3>
<p>Benchmark Electronics Inc is engaged in product designing, engineering services, technology solutions, and manufacturing services (electronic manufacturing services (EMS) and precision technology services). It serves various industries, including aerospace &amp; defense (A&amp;D), medical technologies, complex industrials, semiconductor capital equipment, next-generation telecommunications, and high-end computing. Its geographical segments are the Americas, Asia and Europe of which key revenue is derived from the Americas.</p>
<h3>A Deep Dive into Benchmark Electronics's Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Benchmark Electronics's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately <strong>-4.99%</strong>. This indicates a decrease in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Information Technology sector.</p>
<p><strong>Net Margin:</strong> Benchmark Electronics's net margin excels beyond industry benchmarks, reaching <strong>2.8%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>1.66%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Benchmark Electronics's ROA excels beyond industry benchmarks, reaching <strong>0.86%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Benchmark Electronics's debt-to-equity ratio is below the industry average at <strong>0.33</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<p><a href="https://www.benzinga.com/quote/BHE/earnings"><strong>To track all earnings releases for Benchmark Electronics visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Earnings Preview For Benchmark Electronics

SPRO

Spero Therapeutics Appoints Esther Rajavelu As President And Chief Executive Officer, Effective May 2

<p>Nabors Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NBR#NYSE">NBR</a>) will release its quarterly earnings report on Tuesday, 2025-04-29. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Nabors Industries to report an <strong>earnings per share</strong> (EPS) of $-3.53.</p>
<p>The announcement from Nabors Industries is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Performance in Previous Earnings</h3>
<p>Last quarter the company missed EPS by $4.32, which was followed by a 7.1% drop in the share price the next day.</p>
<p>Here's a look at Nabors Industries's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-2.35</td>
<td>-2.20</td>
<td>-1.85</td>
<td>-1.66</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-6.67</td>
<td>-6.86</td>
<td>-4.29</td>
<td>-4.54</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-7.000000000000001%</td>
<td>-2.0%</td>
<td>10.0%</td>
<td>-5.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745870511_0.png" alt="eps graph" /></p>
<h3>Performance of Nabors Industries Shares</h3>
<p>Shares of Nabors Industries were trading at $29.83 as of April 25. Over the last 52-week period, shares are down 58.99%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. </p>
<h3>Analyst Insights on Nabors Industries</h3>
<p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Nabors Industries.</p>
<p>With 4 analyst ratings, Nabors Industries has a consensus rating of Neutral. The average one-year price target is $51.25, indicating a potential 71.81% upside.</p>
<h3>Peer Ratings Overview</h3>
<p>This comparison focuses on the analyst ratings and average 1-year price targets of Seadrill, Helmerich &amp; Payne and Valaris, three major players in the industry, shedding light on their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Buy trajectory for Seadrill, with an average 1-year price target of $60.25, suggesting a potential 101.98% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Helmerich &amp; Payne, with an average 1-year price target of $28.5, suggesting a potential 4.46% downside.</li>
<li>Analysts currently favor an Neutral trajectory for Valaris, with an average 1-year price target of $42.33, suggesting a potential 41.9% upside.</li>
</ul>
<h3>Peers Comparative Analysis Summary</h3>
<p>Within the peer analysis summary, vital metrics for Seadrill, Helmerich &amp; Payne and Valaris are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nabors Industries</td>
<td>Neutral</td>
<td>0.55%</td>
<td>$140.07M</td>
<td>-51.11%</td>
</tr>
<tr>
<td>Seadrill</td>
<td>Buy</td>
<td>-29.17%</td>
<td>$14M</td>
<td>3.46%</td>
</tr>
<tr>
<td>Helmerich &amp; Payne</td>
<td>Neutral</td>
<td>0.02%</td>
<td>$166.37M</td>
<td>1.84%</td>
</tr>
<tr>
<td>Valaris</td>
<td>Neutral</td>
<td>20.79%</td>
<td>$135.20M</td>
<td>6.14%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Nabors Industries ranks at the bottom for Revenue Growth and Gross Profit, with negative growth and lower profit compared to peers. It also has the lowest Return on Equity among the group. Overall, Nabors Industries lags behind its peers in key financial metrics.</p>
<h3>Unveiling the Story Behind Nabors Industries</h3>
<p>Nabors Industries Ltd owns and operates land-based drilling rig fleets and is a provider of offshore platform rigs in the United States and international markets. It also provides performance tools, directional drilling services, tubular running services, and technologies. The company has four reportable segments: U.S. Drilling, International Drilling, Drilling Solutions, and Rig Technologies. The key revenue of the company is generated from International Drilling.</p>
<h3>Nabors Industries: A Financial Overview</h3>
<p><strong>Market Capitalization Analysis:</strong> Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Nabors Industries's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately <strong>0.55%</strong>. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Energy sector.</p>
<p><strong>Net Margin:</strong> Nabors Industries's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of <strong>-11.43%,</strong> the company may encounter challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Nabors Industries's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>-51.11%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> Nabors Industries's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>-1.84%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> Nabors Industries's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>18.61</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p>
<p><a href="https://www.benzinga.com/quote/NBR/earnings"><strong>To track all earnings releases for Nabors Industries visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Exploring Nabors Industries's Earnings Expectations

<p>SBA Comms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBAC#NASDAQ">SBAC</a>) reported quarterly earnings of $1.77 per share which missed the analyst consensus estimate of $2.24 by 20.98 percent. This is a 24.65 percent increase over earnings of $1.42 per share from the same period last year.  The company reported quarterly sales of $664.25 million which beat the analyst consensus estimate of $661.96 million by 0.35 percent.  This is a 0.97 percent increase over sales of $657.86 million the same period last year.</p>


SBA Comms Q1 EPS $1.77 Misses $2.24 Estimate, Sales $664.25M Beat $661.96M Estimate

<p>Clearwater Paper (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLW#NYSE">CLW</a>) will release its quarterly earnings report on Tuesday, 2025-04-29. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Clearwater Paper to report an <strong>earnings per share</strong> (EPS) of $0.17.</p>
<p>Investors in Clearwater Paper are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Earnings Track Record</h3>
<p>Last quarter the company missed EPS by $0.84, which was followed by a 8.36% drop in the share price the next day.</p>
<p>Here's a look at Clearwater Paper's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.33</td>
<td>0.29</td>
<td>0.30</td>
<td>1.11</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-1.17</td>
<td>0.35</td>
<td>-0.53</td>
<td>1.43</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-8.0%</td>
<td>11.0%</td>
<td>-21.0%</td>
<td>11.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745870503_0.png" alt="eps graph" /></p>
<h3>Market Performance of Clearwater Paper's Stock</h3>
<p>Shares of Clearwater Paper were trading at $24.42 as of April 25. Over the last 52-week period, shares are down 46.01%.  Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. </p>
<h3>Analyst Views on Clearwater Paper</h3>
<p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Clearwater Paper.</p>
<p>A total of 1 analyst ratings have been received for Clearwater Paper, with the consensus rating being Outperform. The average one-year price target stands at $37.0, suggesting a potential 51.52% upside.</p>
<h3>Comparing Ratings Among Industry Peers</h3>
<p>In this analysis, we delve into the analyst ratings and average 1-year price targets of Mercer Intl, Magnera and Sylvamo, three key industry players, offering insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Neutral trajectory for Mercer Intl, with an average 1-year price target of $6.0, suggesting a potential 75.43% downside.</li>
<li>Analysts currently favor an Outperform trajectory for Magnera, with an average 1-year price target of $24.0, suggesting a potential 1.72% downside.</li>
<li>Analysts currently favor an Neutral trajectory for Sylvamo, with an average 1-year price target of $80.0, suggesting a potential 227.6% upside.</li>
</ul>
<h3>Key Findings: Peer Analysis Summary</h3>
<p>The peer analysis summary provides a snapshot of key metrics for Mercer Intl, Magnera and Sylvamo, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clearwater Paper</td>
<td>Outperform</td>
<td>44.12%</td>
<td>$14.70M</td>
<td>26.21%</td>
</tr>
<tr>
<td>Mercer Intl</td>
<td>Neutral</td>
<td>3.81%</td>
<td>$76.18M</td>
<td>3.53%</td>
</tr>
<tr>
<td>Magnera</td>
<td>Outperform</td>
<td>119.11%</td>
<td>$71M</td>
<td>-9.14%</td>
</tr>
<tr>
<td>Sylvamo</td>
<td>Neutral</td>
<td>0.62%</td>
<td>$237M</td>
<td>9.08%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Clearwater Paper ranks at the top for Revenue Growth and Gross Profit among its peers. It is in the middle for Return on Equity.</p>
<h3>Get to Know Clearwater Paper Better</h3>
<p>Clearwater Paper Corp is engaged in the manufacturing and supplier of Solid Bleached Sulfate (SBS) paperboard packaging products. The company products includes: SBS paperboard which is a premium paperboard grade that is frequently used to produce folding cartons, food service, commercial printing items. It generates maximum revenue from Pulp and Paperboard segment. Company operate in United States and have globalized access too. Geographically, it derives maximum revenue from the United States.</p>
<h3>Understanding the Numbers: Clearwater Paper's Finances</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Clearwater Paper's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of <strong>44.12%</strong>. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Materials sector.</p>
<p><strong>Net Margin:</strong> Clearwater Paper's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>51.43%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Clearwater Paper's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>26.21%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Clearwater Paper's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>9.55%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> Clearwater Paper's debt-to-equity ratio is below the industry average at <strong>0.34</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<p><a href="https://www.benzinga.com/quote/CLW/earnings"><strong>To track all earnings releases for Clearwater Paper visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Preview: Clearwater Paper's Earnings

<p><strong>BrightSpire Capital</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRSP#NYSE">BRSP</a>) is set to give its latest quarterly earnings report on Tuesday, 2025-04-29. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that BrightSpire Capital will report an <strong>earnings per share</strong> (EPS) of $0.17. </p>
<p>Anticipation surrounds BrightSpire Capital's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Past Earnings Performance</h3>
<p>During the last quarter, the company reported an EPS missed by $0.00, leading to a 2.18% increase in the share price on the subsequent day.</p>
<p>Here's a look at BrightSpire Capital's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.18</td>
<td>0.19</td>
<td>0.22</td>
<td>0.18</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.18</td>
<td>0.21</td>
<td>0.22</td>
<td>0.23</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>2.0%</td>
<td>18.0%</td>
<td>-8.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745870492_0.png" alt="eps graph" /></p>
<h3>BrightSpire Capital Share Price Analysis</h3>
<p>Shares of BrightSpire Capital were trading at $4.77 as of April 25. Over the last 52-week period, shares are down 21.46%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/BRSP/earnings"><strong>To track all earnings releases for BrightSpire Capital visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Comments

Hubbell

Hubbell (HUBB) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL